BRIEF published on 09/09/2024 at 22:40, 2 years 1 month ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF published on 09/09/2024 at 22:06, 2 years 1 month ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 2 years 1 month ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF published on 08/29/2024 at 18:05, 2 years 2 months ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/06/2024 at 08:35, 2 years 2 months ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
PRESS RELEASE published on 08/06/2024 at 08:30, 2 years 2 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 2 years 3 months ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 2 years 3 months ago ABIVAX: Half-yearly review of the liquidity contract as of June 30, 2024 Liquidity Contract Actions Financial Transactions Abivax First Half Of 2024
BRIEF published on 07/22/2024 at 09:51, 2 years 3 months ago Threshold crossing by Deep Track Biotechnology Master Fund Voting Rights Abivax Crossing Threshold Off-market Acquisition Deep Track Biotechnology
BRIEF published on 07/15/2024 at 22:05, 2 years 3 months ago Abivax announces advances in its clinical program and updates its operations Treasury Ulcerative Colitis Nomination Update Clinical Program
Published on 10/30/2026 at 23:35, 2 days 3 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 3 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 7 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 11 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 16 hours 18 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 21 hours 53 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 10 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 4 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 3 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 14 hours ago Capital increase through exercise of subscription rights
